• organizations:Beacon Therapeutics
Beacon Therapeutics reports positive 24-month phase 2 XLRP gene therapy data
Pipeline

Beacon Therapeutics reports positive 24-month phase 2 XLRP gene therapy data

Latest findings demonstrate AGTC-501 to be generally safe and well-tolerated, with a 57% response rate noted among high-dose-treated eyes. 
Beacon Therapeutics to evaluate patented AAV gene therapy for retinal diseases
Pipeline

Beacon Therapeutics to evaluate patented AAV gene therapy for retinal diseases

Licensing agreement involves potential development and commercialization of Abeona Therapeutics’ patented capsid, a pan-retinal-administered vector.
Beacon Therapeutic raises $170M for XLRP gene therapy development
Pipeline

Beacon Therapeutic raises $170M for XLRP gene therapy development

Funding supports clinical trials on AGTC-501, lead asset designed to address all  photoreceptor damage caused by XLRP.
Beacon Therapeutics doses first patient in VISTA XLRP gene therapy trial
Pipeline

Beacon Therapeutics doses first patient in VISTA XLRP gene therapy trial

Randomized study is investigating AGTC-501 for the treatment of patients diagnosed with x-linked retinitis pigmentosa.
Beacon Therapeutics releases positive 12-month data from phase 2 XLRP trial
Pipeline

Beacon Therapeutics releases positive 12-month data from phase 2 XLRP trial

Latest results find AGTC-501 gene therapy to be safe and well tolerated, demonstrating robust visual function improvements. 
Newly-launched ocular gene therapy company targets blinding retinal diseases
Business

Newly-launched ocular gene therapy company targets blinding retinal diseases

Beacon Therapeutics secures $120 million (£96 million) in financing for an advanced x-linked retinitis pigmentosa program.